Townsquare Capital LLC Sells 17,856 Shares of Abbott Laboratories $ABT

Townsquare Capital LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 61.4% during the third quarter, Holdings Channel reports. The fund owned 11,202 shares of the healthcare product maker’s stock after selling 17,856 shares during the period. Townsquare Capital LLC’s holdings in Abbott Laboratories were worth $1,500,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Charles Schwab Trust Co grew its position in Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after acquiring an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. boosted its stake in shares of Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after purchasing an additional 19,966 shares during the period. Nordea Investment Management AB grew its holdings in shares of Abbott Laboratories by 6.1% in the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after purchasing an additional 18,974 shares during the last quarter. Seaview Investment Managers LLC purchased a new position in shares of Abbott Laboratories in the second quarter worth $11,068,000. Finally, iA Global Asset Management Inc. raised its holdings in Abbott Laboratories by 94.0% during the 3rd quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock valued at $19,296,000 after buying an additional 69,803 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ABT shares. Barclays boosted their price objective on shares of Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Piper Sandler cut their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Wells Fargo & Company upped their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Finally, Daiwa Capital Markets boosted their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.75.

Abbott Laboratories Stock Down 0.0%

Shares of Abbott Laboratories stock opened at $106.03 on Friday. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a 50-day moving average of $123.14 and a 200 day moving average of $127.64. The firm has a market cap of $184.36 billion, a price-to-earnings ratio of 28.50, a PEG ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the prior year, the company earned $1.34 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.